Cargando…
Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma
Ewing sarcoma is the second most common solid bone malignancy diagnosed in pediatric and young adolescent populations. Despite aggressive multi-modal treatment strategies, 5-year event-free survival remains at 75% for patients with localized disease and 20% for patients with metastases. Thus, the ne...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570473/ https://www.ncbi.nlm.nih.gov/pubmed/31231465 http://dx.doi.org/10.18632/oncotarget.26988 |
_version_ | 1783427253113192448 |
---|---|
author | Patel, Priyal O. Pishas, Kathleen I. Taslim, Cenny Selich-Anderson, Julia Theisen, Emily R. Lessnick, Stephen L. |
author_facet | Patel, Priyal O. Pishas, Kathleen I. Taslim, Cenny Selich-Anderson, Julia Theisen, Emily R. Lessnick, Stephen L. |
author_sort | Patel, Priyal O. |
collection | PubMed |
description | Ewing sarcoma is the second most common solid bone malignancy diagnosed in pediatric and young adolescent populations. Despite aggressive multi-modal treatment strategies, 5-year event-free survival remains at 75% for patients with localized disease and 20% for patients with metastases. Thus, the need for novel therapeutic options is imperative. Recent studies have focused on epigenetic misregulation in Ewing sarcoma development and potential new oncotargets for treatment. This project focused on the study of LSD2, a flavin-dependent histone demethylase found to be overexpressed in numerous cancers. We previously demonstrated that Ewing sarcoma cell lines are extremely susceptible to small molecule LSD1 blockade with SP-2509. Drug sensitivity correlated with the degree of LSD2 induction following treatment. As such, the purpose of this study was to determine the role of LSD2 in the epigenetic regulation of Ewing sarcoma, characterize genes regulated by LSD2, and examine the impact of SP-2509 drug treatment on LSD2 gene regulation. Genetic depletion (shRNA) of LSD2 significantly impaired oncogenic transformation with only a modest impact on proliferation. Transcriptional analysis of Ewing sarcoma cells following LSD2knockdown revealed modulation of genes primarily involved in metabolic regulation and nervous system development. Gene set enrichment analysis showed that SP-2509 does not impact LSD2 targeted genes. Although there are currently no small molecule agents that specifically target LSD2, our results support further investigations into agents that can inhibit this histone demethylase as a possible treatment for Ewing sarcoma. |
format | Online Article Text |
id | pubmed-6570473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-65704732019-06-21 Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma Patel, Priyal O. Pishas, Kathleen I. Taslim, Cenny Selich-Anderson, Julia Theisen, Emily R. Lessnick, Stephen L. Oncotarget Research Paper Ewing sarcoma is the second most common solid bone malignancy diagnosed in pediatric and young adolescent populations. Despite aggressive multi-modal treatment strategies, 5-year event-free survival remains at 75% for patients with localized disease and 20% for patients with metastases. Thus, the need for novel therapeutic options is imperative. Recent studies have focused on epigenetic misregulation in Ewing sarcoma development and potential new oncotargets for treatment. This project focused on the study of LSD2, a flavin-dependent histone demethylase found to be overexpressed in numerous cancers. We previously demonstrated that Ewing sarcoma cell lines are extremely susceptible to small molecule LSD1 blockade with SP-2509. Drug sensitivity correlated with the degree of LSD2 induction following treatment. As such, the purpose of this study was to determine the role of LSD2 in the epigenetic regulation of Ewing sarcoma, characterize genes regulated by LSD2, and examine the impact of SP-2509 drug treatment on LSD2 gene regulation. Genetic depletion (shRNA) of LSD2 significantly impaired oncogenic transformation with only a modest impact on proliferation. Transcriptional analysis of Ewing sarcoma cells following LSD2knockdown revealed modulation of genes primarily involved in metabolic regulation and nervous system development. Gene set enrichment analysis showed that SP-2509 does not impact LSD2 targeted genes. Although there are currently no small molecule agents that specifically target LSD2, our results support further investigations into agents that can inhibit this histone demethylase as a possible treatment for Ewing sarcoma. Impact Journals LLC 2019-06-11 /pmc/articles/PMC6570473/ /pubmed/31231465 http://dx.doi.org/10.18632/oncotarget.26988 Text en Copyright: © 2019 Patel et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Patel, Priyal O. Pishas, Kathleen I. Taslim, Cenny Selich-Anderson, Julia Theisen, Emily R. Lessnick, Stephen L. Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma |
title | Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma |
title_full | Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma |
title_fullStr | Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma |
title_full_unstemmed | Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma |
title_short | Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma |
title_sort | investigating the role of lsd2 as an epigenetic regulator in ewing sarcoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570473/ https://www.ncbi.nlm.nih.gov/pubmed/31231465 http://dx.doi.org/10.18632/oncotarget.26988 |
work_keys_str_mv | AT patelpriyalo investigatingtheroleoflsd2asanepigeneticregulatorinewingsarcoma AT pishaskathleeni investigatingtheroleoflsd2asanepigeneticregulatorinewingsarcoma AT taslimcenny investigatingtheroleoflsd2asanepigeneticregulatorinewingsarcoma AT selichandersonjulia investigatingtheroleoflsd2asanepigeneticregulatorinewingsarcoma AT theisenemilyr investigatingtheroleoflsd2asanepigeneticregulatorinewingsarcoma AT lessnickstephenl investigatingtheroleoflsd2asanepigeneticregulatorinewingsarcoma |